Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool helps women decide on HIV prevention

NCT ID NCT05619497

Prevention Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a tablet-based tool and clinic training to help women learn about HIV prevention, including PrEP. 141 women from a Florida clinic participated. The goal was to see if these tools helped women make informed choices and start prevention methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
decision-support tool and clinic training
What this could lead to
If successful, this approach could help more women at risk for HIV learn about and choose prevention methods that fit their lives.
What could go wrong
This is a small, completed study in one clinic, so results may not apply everywhere. It tested a process, not a new drug, so impact depends on how clinics adopt it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

141 people

The number who actually took part.

Started

Dec 2022

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Self-identify as a woman (regardless of pregnancy status) * Age 18 years - 45 years * Not known to be living with HIV (based on self-report) * English speaking * Interested in participating in the study Exclusion Criteria: * Unable to consent * Currently using PrEP * Those who were assigned male at birth and self-identify as a man * Unwilling to be contacted in 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Human immunodeficiency virus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS sexually transmitted disease HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Human immunodeficiency virus Human immunodeficiency virus transmission Sexually transmitted diseases

Contacts and locations

Locations

  • Florida Department of Health, Duval County

    Jacksonville, Florida, 32211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.